Prothena Corporation Earnings Call Transcripts
Fiscal Year 2026
-
The company highlighted its robust pipeline in neurodegenerative and protein misfolding diseases, with major partnered programs advancing in phase III and significant milestone payments expected this year. CYTOPE technology was showcased as a novel platform for targeting intracellular proteins, with further updates anticipated in 2024.
Fiscal Year 2025
-
Advanced key partnered programs into phase 3, introduced CYTOPE technology, and maintained a strong cash position. 2025 financials were favorable to guidance, with 2026 outlook projecting lower cash use and potential $105M in milestones.
-
Multiple late-stage neurology programs are advancing, with phase III trials for Parkinson's and ATTR cardiomyopathy, and key Alzheimer's studies in progress. Transferrin technology may enhance CNS drug delivery, and partnerships are central to strategy. Key data and milestones are expected through 2027.
-
Multiple late-stage partnered programs are advancing, with key milestones and data expected through 2026. Significant financial upside remains from milestone payments and royalties, while new technology and business development initiatives are set to drive further value.
-
Management highlighted recent restructuring, a sharpened focus on partnered programs, and upcoming clinical milestones, including phase 3 trials for prasinezumab and coramitug. Financially, up to $105 million in milestones are expected in 2026, with additional shareholder-friendly actions planned.
Fiscal Year 2024
-
Multiple late-stage programs are nearing key milestones in 2025, including topline phase III results for birtamimab in AL amyloidosis and phase I data for PRX012 in Alzheimer's. 2024 financials met guidance, with strong cash reserves and no debt, supporting continued R&D and commercial buildout.
-
The company is advancing a robust pipeline of protein misfolding therapeutics, with key programs in Alzheimer's, Parkinson's, and amyloidosis. Major milestones include a near-term phase III readout for birtamimab and ongoing innovation in trial design and patient selection.